AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential - May 7th, 2026 6:23 am
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - Apr 16th, 2026 7:00 am
AIM ImmunoTech Provides Routine Update on Annual Filings - Apr 13th, 2026 4:00 pm
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - Apr 9th, 2026 6:00 am
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS - Apr 1st, 2026 7:04 am
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon - Mar 26th, 2026 6:51 am
Aimia Q4 Earnings Call Highlights - Mar 24th, 2026 9:36 am
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Mar 24th, 2026 8:43 am
AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - Mar 24th, 2026 4:00 am
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Mar 18th, 2026 6:36 am
AIM ImmunoTech Announces Closing of its Rights Offering - Mar 6th, 2026 5:00 pm
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Mar 4th, 2026 7:00 am
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - Mar 2nd, 2026 7:00 am
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - Feb 27th, 2026 7:00 am
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - Feb 25th, 2026 7:00 am
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Feb 23rd, 2026 6:55 am
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - Feb 12th, 2026 2:35 pm
AIM ImmunoTech Announces Commencement of Rights Offering - Feb 11th, 2026 6:30 am
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026 - Feb 9th, 2026 9:30 am
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Feb 6th, 2026 6:55 am